Soligenix Secures $7.5 Million Funding to Advance Rare Disease Treatments Through 2026

Soligenix Inc., a late-stage biopharmaceutical company trading on NASDAQ under the symbol SNGX, has successfully closed a $7.5 million public offering that significantly extends the company's financial stability through the end of 2026. The financing involved the sale of 5,555,560 shares of common stock and accompanying warrants at $1.35 per share, with participation from both existing shareholders and institutional healthcare investors.

The capital infusion comes at a critical time for the company's development pipeline and represents a strategic move to ensure uninterrupted progress across multiple therapeutic programs. According to the company announcement available at https://ibn.fm/7omvV, the proceeds will be allocated toward research and development activities, commercialization efforts, working capital requirements, and general corporate purposes. This financial stability is particularly important for a company focused on rare diseases, where development timelines can be lengthy and regulatory pathways complex.

The transaction also included amendments to prior warrants, adjusting their exercise price to $1.35 to align with current market conditions. This financial maneuver demonstrates investor confidence in Soligenix's strategic direction and provides the company with additional flexibility as it advances its clinical programs. The extended cash runway through 2026 provides Soligenix with approximately two and a half years of operational security, allowing the company to focus on key milestones without immediate financial pressure.

Soligenix's Specialized BioTherapeutics business segment is advancing HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Following successful completion of a second Phase 3 study, the company plans to seek regulatory approvals to support potential commercialization worldwide. The company's development pipeline also includes expansion of synthetic hypericin into psoriasis treatment, dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer patients, and SGX945 for Behçet's Disease.

The company's Public Health Solutions division maintains an equally important portfolio, developing RiVax® as a ricin toxin vaccine candidate, along with vaccine programs targeting filoviruses such as Marburg and Ebola. This segment also includes CiVax™, the company's COVID-19 vaccine candidate, all utilizing Soligenix's proprietary ThermoVax® heat stabilization platform technology. These public health initiatives have received support through government grants and contracts from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.

For investors seeking ongoing updates, the company maintains a comprehensive newsroom at https://ibn.fm/SNGX where stakeholders can access the latest developments. The successful financing round represents a significant milestone for Soligenix and the patients who stand to benefit from the company's innovative approaches to treating rare diseases and addressing public health threats.